ATE343571T1 - 4-ä'3-(sulfonylamino)phenyl)'1- (cyclymethyl)piperidin-4- ylidene)methylübenzamidederivate als delta-opioid-rezeptorliganden zur behandlung von schmerzen, angstzuständen und funktionellen gastrointestinalen erkrankungen - Google Patents

4-ä'3-(sulfonylamino)phenyl)'1- (cyclymethyl)piperidin-4- ylidene)methylübenzamidederivate als delta-opioid-rezeptorliganden zur behandlung von schmerzen, angstzuständen und funktionellen gastrointestinalen erkrankungen

Info

Publication number
ATE343571T1
ATE343571T1 AT04701628T AT04701628T ATE343571T1 AT E343571 T1 ATE343571 T1 AT E343571T1 AT 04701628 T AT04701628 T AT 04701628T AT 04701628 T AT04701628 T AT 04701628T AT E343571 T1 ATE343571 T1 AT E343571T1
Authority
AT
Austria
Prior art keywords
cyclymethyl
sulfonylamino
ylidene
anxiety
piperidine
Prior art date
Application number
AT04701628T
Other languages
English (en)
Inventor
William Brown
Andrew Griffin
Christopher Walpole
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE343571T1 publication Critical patent/ATE343571T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT04701628T 2003-01-16 2004-01-13 4-ä'3-(sulfonylamino)phenyl)'1- (cyclymethyl)piperidin-4- ylidene)methylübenzamidederivate als delta-opioid-rezeptorliganden zur behandlung von schmerzen, angstzuständen und funktionellen gastrointestinalen erkrankungen ATE343571T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0300104A SE0300104D0 (sv) 2003-01-16 2003-01-16 Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof

Publications (1)

Publication Number Publication Date
ATE343571T1 true ATE343571T1 (de) 2006-11-15

Family

ID=20290139

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04701628T ATE343571T1 (de) 2003-01-16 2004-01-13 4-ä'3-(sulfonylamino)phenyl)'1- (cyclymethyl)piperidin-4- ylidene)methylübenzamidederivate als delta-opioid-rezeptorliganden zur behandlung von schmerzen, angstzuständen und funktionellen gastrointestinalen erkrankungen

Country Status (10)

Country Link
US (1) US20060148850A1 (de)
EP (1) EP1590346B1 (de)
JP (1) JP2006515352A (de)
AR (1) AR042885A1 (de)
AT (1) ATE343571T1 (de)
DE (1) DE602004002933T2 (de)
ES (1) ES2274415T3 (de)
SE (1) SE0300104D0 (de)
TW (1) TW200500356A (de)
WO (1) WO2004063193A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070099957A1 (en) * 2003-05-16 2007-05-03 Astra Zeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
NZ546834A (en) 2003-10-01 2010-03-26 Adolor Corp Spirocyclic heterocyclic derivatives and methods of their use
US7598261B2 (en) 2005-03-31 2009-10-06 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
US7576207B2 (en) 2006-04-06 2009-08-18 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
IT1396951B1 (it) * 2009-12-18 2012-12-20 Neuroscienze Pharmaness S C A R L Composti farmaceutici

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2898339A (en) * 1957-07-29 1959-08-04 Wm S Merrell Co N-substituted benzhydrol, benzhydryl, and benzhydrylidene piperidine
US4581171A (en) * 1983-07-27 1986-04-08 Janssen Pharmaceutica, N.V. [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones useful for treating psychotropic disorders
US4816586A (en) * 1987-07-29 1989-03-28 Regents Of The University Of Minnesota Delta opioid receptor antagonists
US5140029A (en) * 1989-01-09 1992-08-18 Janssen Pharmaceutica N.V. 2-aminopyrimidinone derivatives
US4939137A (en) * 1989-06-28 1990-07-03 Ortho Pharmaceutical Corporation Ring-fused thienopyrimidinedione derivatives
US5683998A (en) * 1991-04-23 1997-11-04 Toray Industries, Inc. Tricyclic triazolo derivatives, processes for producing the same and the uses of the same
US5574159A (en) * 1992-02-03 1996-11-12 Delta Pharmaceuticals, Inc. Opioid compounds and methods for making therefor
GB9202238D0 (en) * 1992-02-03 1992-03-18 Wellcome Found Compounds
TW548271B (en) * 1996-12-20 2003-08-21 Astra Pharma Inc Novel piperidine derivatives having an exocyclic double bond with analgesic effects
AU2001241676A1 (en) * 2000-03-03 2001-09-17 Ortho-Mcneil Pharmaceutical, Inc. 3-(diarylmethylene)-8-azabicyclo(3.2.1)octane derivatives
US6556387B1 (en) * 2000-03-31 2003-04-29 Seagate Technology Llc Controlling mechanical response characteristics of a disc drive actuator by adjusting a fastener engaging the actuator shaft to vary axial force on the bearing assembly
SE0001207D0 (sv) * 2000-04-04 2000-04-04 Astrazeneca Canada Inc Novel compounds
SE0101766D0 (sv) * 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds
SE0101765D0 (sv) * 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
US20060148850A1 (en) 2006-07-06
SE0300104D0 (sv) 2003-01-16
ES2274415T3 (es) 2007-05-16
WO2004063193A1 (en) 2004-07-29
AR042885A1 (es) 2005-07-06
EP1590346B1 (de) 2006-10-25
JP2006515352A (ja) 2006-05-25
EP1590346A1 (de) 2005-11-02
DE602004002933T2 (de) 2007-09-06
TW200500356A (en) 2005-01-01
DE602004002933D1 (de) 2006-12-07

Similar Documents

Publication Publication Date Title
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
DE602004016992D1 (de) 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3-carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen
NO20055516L (no) Kannabinoidreceptorligander og anvendelser derav
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
NO20054640D0 (no) Fremgangsmater for behandling av Parkinsons sykdom
ATE306482T1 (de) Amine and amide als ligande für den neuropeptid-y y5 rezeptor, und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
ATE448219T1 (de) Neue hydantoinderivate zur behandlung von obstruktiven atemwegserkrankungen
ATE331512T1 (de) Verwendung azetidinone-substituierter verbindungen zur behandlung der sitosterolhämie
ATE371451T1 (de) Duale nk1/nk3 antagonisten zur behandlung von schizophrenie
DE60325770D1 (de) Verwendung von rimexolon zur behandlung von augentrockenheit
ATE447570T1 (de) Pyrimidinderivate zur verwendung als vanilloidrezeptorliganden und deren verwendung bei der behandlung von schmerzen
ATE428694T1 (de) N-ä1h-indol-5-ylünaphthalin-1-sulphonamid- derivate und verwandte verbindungen als serotonin 5-ht6 rezeptor antagonisten zur behandlung von erkrankungen des zentralen nervensystems
ATE486597T1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
ATE539754T1 (de) Arzneinmittelkombinationen enthaltend benzoxazine zur behandlung von atemwegserkrankungen
DE60208221D1 (de) Heterozyklische verbindungen zur behandlung von harnwegserkrankungen
DE69913548D1 (de) Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen
DE602004003952D1 (de) Substituierte tetrahydrobenzothienopyrimidinamine verbindungen geeignet zur behandlung von hyper-proliferative disorders
ATE388712T1 (de) 1-benzyl-5-piperazin-1-yl-3,4 dihydro-1h- chinazolin-2-on-derivate und die jeweiligen 1h- benzo(1,2,6)thiadiazin-2,2-dioxid und 1,4-dihydro-benzo(d)(1,3)oxazin-2-on-derivate als modulatoren des 5-hydroxytryptamin-rezeptors (5-ht) zur behandlung von erkrankungen des zentralen nervensystems
DE60228317D1 (de) N-aryl-n'-arylcycloalkyl-harnstoff als mch antagonisten zur behandlung von fettleibigkeit
DE502004011551D1 (de) 1,3,4-substituierte pyrazole als 5-ht rezeptor-antagonisten zur behandlung von psychosen und neurologischen störungen
DE602004022153D1 (de) Verbindungen zur behandlung von obesitas
DE60030861D1 (de) Verwendung von escitalopram zur Behandlung von generalisierten Angstzuständen
ATE435217T1 (de) 4-(3- (2-phenyl-oxazol-4-ylmethoxy)- cyclohexyloxy)-butansäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
ATE523199T1 (de) Pyridazinverbindungen und verfahren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties